Xcell Biosciences initiates to accelerate its goal by considering new market opportunities in immunotherapy drug research and development. It has exhibited excellence in new immunotherapy treatments consequently leading to demands for new tools and systems that curb primary tumor and immune cells required for clinical applications. Xcell will specialize in modulating phenotypes of primary tumor, stem cell and immune populations in order to met out new applications to cater to the cell therapy drug development and production markets.
Brian S. Feth, Chief Executive Officer at Xcell Biosciences, stated “We are thrilled to have Janette join the Xcell Biosciences team. Janette brings an immense amount of experience in Commercial Development and business leadership to the team, coupled with a strong background in immunology and general cell biology.”
Janette Phi has been appointed to the organization as the Chief Operations Officer who has a prior experience and expertise as chief business officer at IntelliCyt Corporation for over 25 years including other stints as management positions at ForteBio, Guava Technologies, AmCell and Becton Dickinson Biosciences.
Ms Phi expressed excitement over her new stint proclaiming that “the technology has demonstrated its potential impact in cell therapy development through control of the physiological microenvironment, enabling predictive patient responses in precision cancer medicine.”